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Background
For the treatment of metabolic and neurodegenerative
diseases, drug delivery to the central nervous system
(CNS) has gained considerable recent interest [1,2]. But
many concepts for the delivery of therapeutic agents
have failed by the natural blood-brain barrier (BBB).
The N2B route for drugs is able to provide an adequate
alternative of CNS drug delivery -bypassing the BBB [3,4].
N2B drug transport takes mainly place at the olfactory
cleft, an area that is well hidden in the skull base [5]. In
a previous study, we determined the characteristics of
aerosols for optimal deposition for N2B delivery by a com-
putational approach and validated those data with experi-
mental deposition in a human nose model generated by
rapid prototyping [manuscript in preparation]. With the
determined criteria, different aerosol generators were eval-
uated for protein dispersion. Moreover, a surrogate
method was developed that imitates the dispersion effect
was used for formulation screening to maintain stability
and function and to avoid shear stress during dispersion.
The most promising protein formulations were tested in
an in vitro exposition system for passage through a nasal
epithelium in a transwell culture. This test system can be
used to develop an N2B platform approach.
Material and methods
The Carleton-civic standardized human nose model [6]
was constructed from CT scans and displays the complex
3D geometry of the human nose and its olfactory cleft.
The deposition of liquid airborne aerosols was simulated
numerically by computational fluid and particle dynamics
(CFPD). Those data were validated experimentally in a
positive rapid prototyped human nose model. A surro-
gate agitation method, imitating the dispersion effect was
applied for formulation screening within a Design of
Experiment (DoE) approach using trehalose (0.5-6%
(w/v)), sorbitol (0.5-5 % (w/v)), arginine (0.5 - 5 % (w/v)),
tween (0.005-0.05 % (v/v)) and cyclodextrin (0.35-3.5 %
(v/v)). Protein stability was evaluated applying SE-HPLC
and photometry to determine monomer content before
and after dispersion with a vibrating mesh nebulizer
(Aeroneb Pro, Aerogen 112 Inc., Galway, Ireland). Identi-
fied suitable formulations were exposed to a nasal epithe-
lial cell line (RPMI 2650) growing on transwell inserts to
investigate transport ratios. Therefore, various seeding
densities and transwells were tested under submers and
air-liquid interface (ALI) conditions. The confluence of a
monolayer was investigated with confocal microscopy by
staining adhesion and tight junction proteins and a valid
transport model was established with FITC-dextran in
the Vitrocell® Cloud System (Waldkirch, Germany).
Finally, two formulations were further analyzed in detail
to study molecular weight, concentration and formula-
tion dependencies on transport ratios.
Results and discussion
In the present study, we found that aerosol parameters had
to be defined very precisely to enable deposition at the ana-
tomically hidden olfactory cleft. Validation of CFPD simula-
tion by the experimental nose model determined a particle
size of 5-10 µm and a flow rate of 5-20 L/min as optimal
conditions for improved deposition.
However, aerosol generation may cause shear stress
that correlates with protein instability. Therefore, a
vibrating mesh nebulizer was identified as suitable aero-
sol source that fulfills the requirements and specifications
concerning particle size, flow rate, chemical and physical
properties as well as material and cost. Nevertheless,
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dispersion is time and material consuming and hence, a
surrogate method was established by agitation in a 96-
well plate. An antibody Fab fragment was diluted in sim-
ple PBS formulations containing either cyclodextrin (0.35
and 3.5 % (w/v)), tween (0.05, 0.01, 0.005 % (v/v)) or argi-
nine (2, 5 and 8 % (w/v)) and they were agitated at 900
rpm, 30 °C for 20 min. Turbidities after dispersion and
agitation were measured and showed a significant corre-
lation of R2 = 0.8688. Using the surrogate method, the
formulation screen led to suitable formulations. The
most promising formulation 1 (trehalose (1 % (w/v)), sor-
bitol (4% (w/v)), arginine (5% (w/v)), tween (0.028 %(v/v))
and cyclodextrin (0.35% (w/v))) revealed improved pro-
tein stability compared to the parental formulation (PBS)
for different antibody formats as Fab, IgG A and IgG B
after dispersion (Table 1).
To test the effects of different formulations on absorp-
tion on a nasal epithelium, we used a transwell system
that is exposed to ALI. The system was characterized by
FITC-dextran transport studies and confocal microscopy
that confirmed tight junctions and a monolayer. IgG A
and its Fab fragment was formulated and dispersed in
the Vitrocell® Cloud system and transwells were trans-
ferred to the incubator for 4 h to study transport ratios.
A correlation between molecular size and concentration
was observed regarding transport ratios. Fab showed a
significant improved diffusion compared to IgG A at
equivalent molarities. Using two different IgG concen-
trations revealed a significant faster diffusion for the
higher concentration (Figure 1).
Conclusions
In conclusion, shear stress and dispersion effects had a
strong impact on protein aggregation when generating
micrometer-sized particles. Here, we present the estab-
lishment of a surrogate method imitating the dispersion
effect and the subsequent formulation screen that led to
improved protein stability after dispersion. Moreover, an
in vitro exposition system was optimized to study trans-
port ratios of different molecular weight sized proteins,
concentrations and formulations. As aggregated proteins
appear and cause a proinflammatory reaction, the nasal-
epithelial cells will be co-cultivated with macrophages to
study signs of immunogenicity after dispersion. These
results will be verified in in vivo.
In summary, this test system is suitable to be used
asN2B platform for protein aerosols. That includes par-
ticle size, deposition in experimental and in silico nose
Table 1. Formulation and stability: Fab, IgG A and IgG B were dispersed and analyzed via SE-HPLC comparing
monomer content before and after dispersion (n = 3, ± SD)
Formulation 1 PBS
Constructs undispersed dispersed undispersed dispersed
Fab 103.21 ± 3.62 90.27 ± 6.87 (ns) 100.00 ± 0.53 77.86 ± 2.44 (**)
IgG A 103.17 ± 0.12 101.27 ± 2.79 (ns) 100.00 ± 0.28 86.92 ± 2.99 (**)
IgG B 92.72 ± 4.51 74.88 ± 5.15 (**) 100.00 ± 3.09 77.15 ± 4.12 (***)
For statistical analysis unpaired two-tailed t-Test was applied to compare undispersed with dispersed samples for each formulation (**p<0.01, ***p<0.001).
Figure 1 Transport of protein aerosols in formulation 1 and PBS in a human nose epithelial cell model (n = 3, ± SD). A) transport ratios
of different molecular weight sized proteins - Fab and IgG A. B) cells were exposed to two different IgG A concentrations. C) The influence of
formulations on the transport ratio. For statistical analysis an unpaired two-tailed t-Test was applied (*p<0.05, **p<0.01, ***p<0.001).
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model, protein stability, in vitro and later on in vivo
studies.
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